Avoid common mistakes on your manuscript.
1 Correction to: Drugs (2017) 77:2013–2024 https://doi.org/10.1007/s40265-017-0837-7
The author has alerted us to the following error in Sect. 4.2.2.1, and the following correction should be noted:
Page 2019, Sect. 4.2.2.1, paragraph 1, lines 6–10: the following sentence, which previously read:
“After a median follow-up of 24.5 months, daratumumab plus lenalidomide and dexamethasone was still associated with significantly (p < 0.0001) prolonged median PFS relative to lenalidomide plus dexamethasone (not reached vs. 17.5 months; HR 0.41; 95% CI 0.31–0.53)”.
should read:
“After a median follow-up of 25.4 months, daratumumab plus lenalidomide and dexamethasone was still associated with significantly (p < 0.0001) prolonged median PFS relative to lenalidomide plus dexamethasone (not reached vs. 17.5 months; HR 0.41; 95% CI 0.31–0.53)”.
Author information
Authors and Affiliations
Corresponding author
Additional information
The original article can be found online at https://doi.org/10.1007/s40265-017-0837-7.
Rights and permissions
About this article
Cite this article
Blair, H.A. Correction to: Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma. Drugs 78, 397 (2018). https://doi.org/10.1007/s40265-018-0873-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-018-0873-y